News
CeNeS Pharmaceuticals Plc: CeNeS Pharmaceuticals plc ("CeNeS" or "the Company"): Proposed placing to raise £6.1m and consolidation of share capital
The Company is pleased to announce that it proposes to raise approximately £6.1 million (before expenses) by means of a placing ("the Placing") of 5,789,137 new ordinary shares (the "Placing Shares") of 30 pence each ("New Ordinary Shares") at 105 pence per share. The placing price of 105 pence per share, reflects the proposed 30 for one consolidation of the ordinary share capital of the Company. The Directors intend to use the net proceeds of the Placing to prepare for Phase III studies of its lead drug M6G (morphine-6-glucuronide) in the United States and to carry out clinical trials of its other products, further details of which are set out below. The Placing is conditional, inter alia, on the passing of the necessary resolutions at an Extraordinary General Meeting of the Company ("the EGM") to be held on 22 August 2007. The Company will also hold its Annual General Meeting on the same date.
Read more »
Neose Closes $43 Million Private Placement of Common Stock and Warrants
HORSHAM, Pa.--(BUSINESS WIRE)--March 13, 2007 Neose Technologies, Inc. (Nasdaq:NTEC) today announced that it has closed its previously announced private placement. The Company sold 21,415,447 shares of common stock and warrants to purchase 9,636,950 shares of its common stock at a price of $2.02 per unit. Each unit consists of one share of common stock and a warrant to purchase 0.45 shares of common stock. The warrants have a term of five years and an exercise price of $1.96 per share. The Company realized gross proceeds of approximately $43.3 million. Both new and existing investors participated in the private placement.
Read more »
Events
4th Annual Asia Pacific Life Sciences Forum
Following three consecutive years of success, the 4th Annual Asia Pacific Life Sciences Forum will showcase a select group of Asia Pacific biotechnology companies to UK & EU investor and partnering audiences interested in the Asia Pacific region. Attendance is free for media, qualifying analysts, fund managers, investors, venture capitalists, biotech and pharma executives.
Day One is a closed briefing session for Presenting Companies with scheduled partnering meetings taking place in the afternoon, while Day Two is open for all delegates to attend and hear the Company presentations. Formal and informal networking functions will include an evening hosted by the Governor of Victoria Professor David de Kretser.
Organising sponsors include Intersuisse BioScience Managers, Elixir Securities, Grant Thornton and Northbank Communications. For more information, please visit http://www.aplsf.com or contact Intersuisse Elizabeth Steyn on +61 (0)3 9629 8380 or esteyn@intersuisse.com.au